[1] |
DORSEY E R, BLOEM B R. The Parkinson pandemic-a call to action[J]. JAMA Neurol, 2018, 75(1):9-10. doi:10.1001/jamaneurol.2017.3299.
|
[2] |
SCHAPIRA A H V, CHAUDHURI K R, JENNER P. Non-motor features of Parkinson disease[J]. Nat Rev Neurosci, 2017, 18(7):435-450. doi:10.1038/nrn.2017.62.
|
[3] |
ROCHA E M, DE MIRANDA B, SANDERS L H. Alpha-synuclein:Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease[J]. Neurobiol Dis, 2018, 109(Pt B):249-257. doi:10.1016/j.nbd.2017.04.004.
|
[4] |
杜可晨, 邹春林. 基于α-突触核蛋白的帕金森病动物模型研究进展[J]. 天津医药, 2021, 49(5):550-555.
|
|
DU K C, ZOU C L. Current progress in α -synuclein-based animal models of Parkinson's disease[J]. Tianjin Med J, 2021, 49(5):550-555. doi:10.11958/20202907.
|
[5] |
BLUMENSTOCK S, RODRIGUES E F, PETERS F, et al. Seeding and transgenic overexpression of alpha-synuclein triggers dendritic spine pathology in the neocortex[J]. EMBO Mol Med, 2017, 9(5):716-731. doi:10.15252/emmm.201607305.
|
[6] |
KARAMPETSOU M, ARDAH M T, SEMITEKOLOU M, et al. Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice[J]. Sci Rep, 2017, 7(1):16533. doi:10.1038/s41598-017-15813-8.
|
[7] |
VISANJI N P, BROTCHIE J M, KALIA L V, et al. alpha-Synuclein-based animal models of Parkinson's disease:challenges and opportunities in a new era[J]. Trends Neurosci, 2016, 39(11):750-762. doi:10.1016/j.tins.2016.09.003.
|
[8] |
EL-HORANY H E, EL-LATIF R N, ELBATSH M M, et al. Ameliorative effect of quercetin on neurochemical and behavioral deficits in rotenone rat model of Parkinson's disease:modulating autophagy (quercetin on experimental Parkinson's disease)[J]. J Biochem Mol Toxicol, 2016, 30(7):360-369. doi:10.1002/jbt.21821.
|
[9] |
RECASENS A, DEHAY B, BOVE J, et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys[J]. Ann Neurol, 2014, 75(3):351-362. doi:10.1002/ana.24066.
|
[10] |
LI W, ENGLUND E, WIDNER H, et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain[J]. Proc Natl Acad Sci USA, 2016, 113(23):6544-6549. doi:10.1073/pnas.1605245113.
|
[11] |
CREED R B, MEMON A A, KOMARAGIRI S P, et al. Analysis of hemisphere-dependent effects of unilateral intrastriatal injection of α-synuclein pre-formed fibrils on mitochondrial protein levels,dynamics,and function[J]. Acta Neuropathol Commun, 2022, 10(1):78. doi:10.1186/s40478-022-01374-z.
|
[12] |
MARMION D J, KORDOWER J H. α-synuclein nonhuman primate models of Parkinson's.disease[J]. J Neural Transm(Vienna), 2018, 125(3):385-400. doi:10.1007/s00702-017-1720-0.
|
[13] |
MARIN C, VILAS D, LANGDON C, et al. Olfactory dysfunction in neurodegenerative diseases[J]. Curr Allergy Asthma Rep, 2018, 18(8):42. doi:10.1007/s11882-018-0796-4.
|
[14] |
BRAAK H, DEL TREDICI K, RUB U, et al. Staging of brain pathology related to sporadic Parkinson's disease[J]. Neurobiol Aging, 2003, 24(2):197-211. doi:10.1016/s0197-4580(02)00065-9.
|
[15] |
HUISMAN E, UYLINGS H B, HOOGLAND P V. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease[J]. Mov Disord, 2004, 19(6):687-692. doi:10.1002/mds.10713.
|
[16] |
XIE M Q, CHEN Z C, ZHANG P, et al. Newborn dopaminergic neurons are associated with the migration and differentiation of SVZ-derived neural progenitors in a 6-hydroxydopamin-injected mouse model[J]. Neuroscience, 2017, 352:64-78. doi:10.1016/j.neuroscience.2017.03.045.
|
[17] |
BANG Y, LIM J, CHOI H J. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease:clues to early diagnosis and effective treatment[J]. Arch Pharm Res, 2021, 44(6):588-604. doi:10.1007/s12272-021-01337-3.
|
[18] |
WINNER B, REGENSBURGER M, SCHREGLMANN S, et al. Role of alpha-synuclein in adult neurogenesis and neuronal maturation in the dentate gyrus[J]. J Neurosci, 2012, 32(47):16906-16916. doi:10.1523/JNEUROSCI.2723-12.2012.
|